USFDA had declined to approve Eli Lilly’s drug to treat ulcerative colitis Mirikizumab andissued a Complete Response (CR) letter citing issues related to the manufacturing of Mirikizumab. Eli Lilly had received an FDA Form 483 citing manufacturing issues at its Branchburg, New Jersey facility (As per a Reuters report) Read More..